Peter Stein Takes Short Path To Director Of US FDA Drug Office
Peter Stein Takes Short Path To Director Of US FDA Drug Office
$131.00
After only a short stint at the US FDA as Deputy Director of the Office of New Drugs, industry veteran Peter Stein was appointed to his permanent post as Director of the OND in December of 2018, filling a role that sat vacant for nearly two years.
Author: Derrick Gingery
Publisher: Pinksheet
- Description
With the appointment of pharmaceuticals veteran Peter Stein as Director of the US FDA’s Office of New Drugs in December of 2018 comes the promise of further restructuring at the agency. The appointment announcement came alongside the news that seasoned FDA veteran Robert Temple would be moving from his post as acting Deputy Director of ODE I to serve as a consultant on matters of clinical trials to both Stein and other FDA officials. Read more about the changes to FDA staffing in this informative Pink Sheet article.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Gilead Lures Roche Pharma CEO O’Day As CEO; Genentech’s CEO Will Replace... 
Sign up to the